Effects Of Dose Reduction On Geincitabine-Based Neoadjuvant Chemoradiotherapy For Localized Pancreatic Cancer

e15262 Background: Patients receiving gemcitabine-based neoadjuvant chemoradiotherapy for non-metastatic pancreatic cancer often have difficulty tolerating full treatment courses. Providers are thus faced with the difficult decision of holding or reducing chemotherapy. As the effects of chemotherapy dose reduction are not well understood, we evaluated the impact of dose reduction on survival and other outcomes. Methods: We performed a single center retrospective review of patients receiving two gemcitabine-based neoadjuvant chemoradiation protocols for localized pancreatic cancer over a 9 year period. For inclusion, patients were required to have completed at least 95% of their prescribed radiation dose. The dose intensity of completed chemotherapy was stratified into three tiers of 90%-100%, 75%-89%, and u003c75% of total protocol dose. Our primary outcome was the effect of dose reduction on overall and progression-free survival. Secondary outcomes included completion of surgery, radiologic down staging, R0 ...